Advertisement

Screening for Prostate Cancer: Practical Aspects

  • F. H. Schröder

Abstract

A major European randomised study of screening for prostate cancer has been launched. Pilot studies have already been conducted in several centres, and working groups in Belgium, Italy and the Netherlands are confirmed participants. Working parties in Finland, Portugal and the United Kingdom are candidate participants.

Keywords

Prostate Cancer Radical Prostatectomy Digital Rectal Examination Cancer Detection Rate Prostate Cancer Mortality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bentvelsen FM, Schröder FH (1993) Modalities available for screening for prostate cancer. Eur J Cancer 29A(6):804–811PubMedCrossRefGoogle Scholar
  2. Boyle P, Alexander FE (1994) Screening for prostate cancer: principles, design and evaluation, European Institute of Oncology Technical Report 94/005. European Institute of Oncology, Milan, ItalyGoogle Scholar
  3. Catalona WJ, Smith DS, Ratliff TL et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161PubMedCrossRefGoogle Scholar
  4. Colberg JW, Smith DS, Catalona WJ (1993) Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0ng/ml. J Urol 149:507–509PubMedGoogle Scholar
  5. de Koning HJ (1993) Grant appliction to the Dutch Cancer Society and Prevention FundGoogle Scholar
  6. Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumour extent of non-palpable (stage Tlc) prostate cancer. JAMA 2715:368–374PubMedCrossRefGoogle Scholar
  7. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez J-L, Emond J (1992) Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 147:846–852PubMedGoogle Scholar
  8. Mettlin C, Lee F, Drago J, Murphy GP, Investigators of the American Cancer Society National Prostate Cancer Detection Project (1991) The American Cancer Society National Prostate Cancer Detection Project. Cancer 67:2949–2958PubMedCrossRefGoogle Scholar
  9. Oesterling JE, Jacobsen SJ, Chute CG et al (1993) Serum prostate specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270:860–864PubMedCrossRefGoogle Scholar
  10. Oesterling JE, Martin SK, Bergstrahl EJ, Lowe FC (1993) The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269(l):57–60PubMedCrossRefGoogle Scholar
  11. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT (1994) The pathological features and prognosis of prostate cancers detectable with current tests. J Urol (in press)Google Scholar
  12. Prorok PC (1991) PLCO study proposal. Biometry and Early Detection Branches, National Cancer Institute, USAGoogle Scholar
  13. Schröder FH (1993) Prostate cancer: to screen or not to screen? Br Med J 306:407CrossRefGoogle Scholar
  14. Schröder FH, Boyle P (1963) Screening for prostate cancer — necessity or nonsense? Eur J Cancer 29:656CrossRefGoogle Scholar
  15. Schröder FH, Denis L, Kirkels WJ, de Koning HJ, Standaert B (1994) European randomised study of screening for prostate cancer. Cancer (in press)Google Scholar
  16. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP (1993) Localised prostate cancer. Relationship of tumour volume to clinical significance for treatment of prostate cancer. Cancer 71:933–938PubMedCrossRefGoogle Scholar
  17. Wilson JMG, Jungner G (1968) Principles and practice of screening for disease Public Health Paper no 34. WHO, GenevaGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • F. H. Schröder

There are no affiliations available

Personalised recommendations